Durvalumab and Tremelimumab for Pediatric Malignancies
Status:
Recruiting
Trial end date:
2023-12-22
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab
(immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and
expand in a second phase to test the efficacy of these drugs once this dose is determined